BR0113555A - Processo e aparelho para remover pelo menos um dentre cátions de ferro e zinco de uma composição de banho de autodeposição - Google Patents

Processo e aparelho para remover pelo menos um dentre cátions de ferro e zinco de uma composição de banho de autodeposição

Info

Publication number
BR0113555A
BR0113555A BR0113555-4A BR0113555A BR0113555A BR 0113555 A BR0113555 A BR 0113555A BR 0113555 A BR0113555 A BR 0113555A BR 0113555 A BR0113555 A BR 0113555A
Authority
BR
Brazil
Prior art keywords
iron
self
zinc cations
cations
iex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0113555-4A
Other languages
English (en)
Inventor
Donald Herbert Hprtsman
Claire Julia Maden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0113555A publication Critical patent/BR0113555A/pt
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

"PROCESSO E APARELHO PARA REMOVER PELO MENOS UM DENTRE CáTIONS DE FERRO E ZINCO DE UMA COMPOSIçãO DE BANHO DE AUTODEPOSIçãO". São descritos um método e aparelho para remover cátions de ferro e/ou cátions de zinco de um banho de revestimento de autodeposição (T1), pela passagem de um número limitado de volumes de leito através de uma coluna (IEX) contendo uma resina IEX SAC tipo gel, quando os cátions de ferro são para ser removidos e pela passagem de um número substancialmente maior de volumes de leito através da coluna (IEX), quando cátions de zinco são para ser removidos. Para impedir a obstrução quando os cátions de zinco estão sendo removidos, a direção do fluxo, através da coluna (IEX), é periodicamente invertida.
BR0113555-4A 2000-08-31 2001-08-31 Processo e aparelho para remover pelo menos um dentre cátions de ferro e zinco de uma composição de banho de autodeposição Pending BR0113555A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22938100P 2000-08-31 2000-08-31
PCT/GB2001/003928 WO2002017894A2 (en) 2000-08-31 2001-08-31 Pharmaceutical formulation of salmeterol and fluticasone propionate

Publications (1)

Publication Number Publication Date
BR0113555A true BR0113555A (pt) 2003-07-22

Family

ID=22860986

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113555-4A Pending BR0113555A (pt) 2000-08-31 2001-08-31 Processo e aparelho para remover pelo menos um dentre cátions de ferro e zinco de uma composição de banho de autodeposição

Country Status (24)

Country Link
US (1) US20040009963A1 (pt)
EP (1) EP1313484A2 (pt)
JP (1) JP2004507494A (pt)
KR (1) KR20030031997A (pt)
CN (1) CN1449288A (pt)
AP (1) AP2003002753A0 (pt)
AR (1) AR030516A1 (pt)
AU (1) AU2001284236A1 (pt)
BG (1) BG107596A (pt)
BR (1) BR0113555A (pt)
CA (1) CA2420532A1 (pt)
EA (1) EA200300152A1 (pt)
EC (1) ECSP034487A (pt)
HU (1) HUP0303755A2 (pt)
IL (1) IL154403A0 (pt)
MA (1) MA25834A1 (pt)
MX (1) MXPA03001752A (pt)
NO (1) NO20030899L (pt)
OA (1) OA12370A (pt)
PE (1) PE20020387A1 (pt)
PL (1) PL365582A1 (pt)
SK (1) SK2302003A3 (pt)
WO (1) WO2002017894A2 (pt)
ZA (1) ZA200301475B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
WO2005013963A1 (en) * 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
TR200907913A2 (tr) * 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
TR200909791A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2014177519A1 (en) * 2013-04-29 2014-11-06 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2024033624A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for the treatment of moderate chronic obstructive pulmonary disease (copd)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
AU2206801A (en) * 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Also Published As

Publication number Publication date
SK2302003A3 (en) 2003-08-05
US20040009963A1 (en) 2004-01-15
IL154403A0 (en) 2003-09-17
WO2002017894A2 (en) 2002-03-07
BG107596A (bg) 2004-01-30
ECSP034487A (es) 2003-03-31
OA12370A (en) 2004-03-19
MXPA03001752A (es) 2003-06-04
CA2420532A1 (en) 2002-03-07
AP2003002753A0 (en) 2003-06-30
EP1313484A2 (en) 2003-05-28
PL365582A1 (en) 2005-01-10
WO2002017894A3 (en) 2002-08-08
NO20030899L (no) 2003-04-28
JP2004507494A (ja) 2004-03-11
AR030516A1 (es) 2003-08-20
AU2001284236A1 (en) 2002-03-13
HUP0303755A2 (hu) 2004-04-28
EA200300152A1 (ru) 2003-08-28
CN1449288A (zh) 2003-10-15
PE20020387A1 (es) 2002-06-24
ZA200301475B (en) 2004-05-24
MA25834A1 (fr) 2003-07-01
KR20030031997A (ko) 2003-04-23
NO20030899D0 (no) 2003-02-26

Similar Documents

Publication Publication Date Title
BR0113555A (pt) Processo e aparelho para remover pelo menos um dentre cátions de ferro e zinco de uma composição de banho de autodeposição
DE59600451D1 (de) Verfahren zur Regenerierung eines Katalysators
ES2194852T3 (es) Inhibidor de metaloproteinasa de tejido de tipo tres (timp-3).
RU93058414A (ru) Способы использования фибринового герметика, способ получения состава, составы, наборы
FR2767522B1 (fr) Procede et dispositif de traitement de l'eau par injection d'ozone et de dioxyde de carbone
FR2709678B1 (fr) Procédé d'épuration d'effluents gazeux ou liquides contenant des dérivés soufrés.
BR9911137A (pt) Processo para tratamento de correntes de fluido
ES2089402T3 (es) Polimeros que contienen acido fosfinico y su utilizacion en la prevencion de la incrustacion y corrosion.
OA09457A (fr) Procédé pour la valorisation des boues d'épuration.
BR0113497A (pt) Processo e aparelho para remover pelo menos um dentre cations de ferro e zinco de uma composição de banho de autodeposição
BR0114081A (pt) Processo para a regeneração de catalisador heterogêneo
SE9502259L (sv) Oligonukleotider för att inhibera expression av isoprenylproteintransferas
ATE170900T1 (de) Beschichtungsmittelgranulat und verfahren zu dessen herstellung
BE603900A (fr) Procédé et installation de clarification d'eaux résiduaires, au moyen de boue activée
DK0655987T3 (da) Påfyldningsblok
ES2100472T3 (es) Metodo de regenerar perlas de resina para empleo en purificacion de agua.
ES8704852A1 (es) Procedimiento para depurar azufre liquido
PT1070022E (pt) Dispositivo para o tratamento de agua
JPS51148971A (en) Surfactant containing waste water treatment
FR2673143B1 (fr) Procede pour traiter des blocs de caoutchouc contenant de l'acier.
BR9806538A (pt) Composição fotocurável, processo sintético, processo para formar uma composição fotocurável dispersìvel em água, e, elemento fotocurável
GB1336281A (en) Hydrocarbon binding complex process for its preparation and applications thereof
BR9813052A (pt) Processo contìnuo para a preparação de aminas aromáticas
FR2552752B1 (fr) Procede pour l'epuration d'eaux residuaires chargees de substances organiques au moyen de materiaux adsorbants
FR2040874A5 (en) Purification of acrylic acid for high-molecul - ar flocculent polymers

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]